Who We Are
Our Team
Led by Executive Director Matthew Halma and Scientific Director Prof Jack A. Tuszynski — researchers with a combined track record of 400+ peer-reviewed publications and active clinical trial programmes.
Meet the Team →Research Experience
Our Experience
Our directors have previously published extensively in top journals across our three main focuses — repurposed drugs for chronic conditions, post-viral syndromes and PACVS, and environmental health and drug safety. Our work is cited by national advisory committees on PACVS and continues to shape clinical treatment and health policy.
View Our Experience →Strategic Priorities
Our Priorities
Three interlocking initiatives: evidence synthesis for repurposed drugs, a post-viral syndromes biobank, and consensus-based diagnostic criteria for PACVS.
Our Priorities →